These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20631586)

  • 1. Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
    Yang X; Yuan W; Ren T; Song L; Wu N; Liu Z
    Neuroreport; 2010 Aug; 21(12):837-40. PubMed ID: 20631586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
    Yang X; Chen Y; Hong X; Wu N; Song L; Yuan W; Liu Z
    Drug Des Devel Ther; 2012; 6():341-7. PubMed ID: 23185117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
    Ren T; Yang X; Wu N; Cai Y; Liu Z; Yuan W
    Neurosci Lett; 2011 Sep; 502(2):117-22. PubMed ID: 21835223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH; Henry B; Hill M; Crossman A; Brotchie J
    Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
    Yang X; Zheng R; Cai Y; Liao M; Yuan W; Liu Z
    Int J Nanomedicine; 2012; 7():2077-86. PubMed ID: 22619544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
    Kapitsa IG; Ivanova EA; Nepoklonov AV; Kokshenev II; Voronina TA; Val'dman EA
    Eksp Klin Farmakol; 2011; 74(7):9-12. PubMed ID: 21894760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F; Millan MJ; Brocco M; Morari M
    Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats.
    Arica B; Kaş HS; Moghdam A; Akalan N; Hincal AA
    J Control Release; 2005 Feb; 102(3):689-97. PubMed ID: 15681090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
    Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Aguiar AS; Moreira EL; Hoeller AA; Oliveira PA; Córdova FM; Glaser V; Walz R; Cunha RA; Leal RB; Latini A; Prediger RD
    Neuroscience; 2013 Jul; 243():46-53. PubMed ID: 23558088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.